---
title: "Shanghai Junshi Biosciences Sets Board Meeting to Approve Q1 2026 Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282830459.md"
description: "Shanghai Junshi Biosciences Co., Ltd. has scheduled a board meeting for April 27, 2026, to approve its unaudited financial results for Q1 2026. This meeting will provide stakeholders with insights into the company's financial and operational performance. The board, led by Mr. Xiong Jun, will oversee the approval process, aligning with standard disclosure practices in the Hong Kong market. The latest analyst rating for the stock (HK:1877) is a Hold, with a price target of HK$34.70."
datetime: "2026-04-15T10:53:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282830459.md)
  - [en](https://longbridge.com/en/news/282830459.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282830459.md)
---

# Shanghai Junshi Biosciences Sets Board Meeting to Approve Q1 2026 Results

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest announcement is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).

Shanghai Junshi Biosciences Co., Ltd. has scheduled a board meeting for April 27, 2026, to review and approve the group’s unaudited financial results for the three months ended March 31, 2026. The announcement signals the upcoming release of the company’s first-quarter performance, which will provide investors and other stakeholders with an early view of its financial and operational trajectory for the year.

The board, chaired by Mr. Xiong Jun and comprising executive, non-executive and independent non-executive directors, will oversee the approval of these results in Shanghai. The timing of the meeting aligns with standard disclosure practices on the Hong Kong market and suggests the company is preparing to update the market on recent business developments and financial health.

The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.

**More about Shanghai Junshi Biosciences Co., Ltd. Class H**

Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in the People’s Republic of China and listed in Hong Kong under stock code 1877. The group focuses on the research, development and commercialization of innovative therapies, positioning itself within China’s rapidly developing biotech and pharmaceutical sector.

**Average Trading Volume:** 3,778,716

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** HK$43.32B

### Related Stocks

- [01877.HK](https://longbridge.com/en/quote/01877.HK.md)
- [688180.CN](https://longbridge.com/en/quote/688180.CN.md)

## Related News & Research

- [Junshi Biosciences Board Approves 2026 Q1 Report at Fully Attended Meeting](https://longbridge.com/en/news/284233708.md)
- [Shanghai Junshi Biosciences Schedules 2025 Results Briefing for Investor Q&A](https://longbridge.com/en/news/279928612.md)
- [China XLX Announces 2026 Q1 Results | CXLFF Stock News](https://longbridge.com/en/news/286673637.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Crombie Reit Announces May 2026 Monthly Distribution | CROMF Stock News](https://longbridge.com/en/news/286603129.md)